X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Rhofade (oxymetazoline hydrochloride) cream is an FDA-approved prescription topical treatment that may reduce persistent facial redness by at least two grades, according to both doctor and patient scales that evaluated rosacea redness in two 29-day trials in adults.
Lead Product(s): Oxymetazoline Hydrochloride
Therapeutic Area: Dermatology Product Name: Rhofade
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sato Yakuhin Kogyo Co., Ltd
Deal Size: $7.5 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement December 21, 2022
Details:
WYNZORA Cream is a fixed dose combination of calcipotriene and betamethasone dipropionate used for the topical treatment of plaque psoriasis. Betamethasone dipropionate has anti-inflammatory effects resulting in decreased expression of key TNF-α, IL-17A/F and IL-23 cytokines.
Lead Product(s): Berdazimer Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: SB206
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Novan
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2022
Details:
WYNZORA is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis. It is based on PAD™ Technology, which enables stability of both calcipotriene and betamethasone dipropionate in aqueous formulation.
Lead Product(s): Calcipotriol,Betamethasone Dipropionate
Therapeutic Area: Dermatology Product Name: Wynzora
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: MC2 Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2022
Details:
Collaboration accelerates a Q1 2021 comprehensive launch of MC2’s WYNZORA® Cream to patients with plaque psoriasis in the US. WYNZORA® Cream is the first drug based on PADTM Technology – providing innovative solutions to unmet needs in chronic inflammatory conditions.
Lead Product(s): Calcipotriol,Betamethasone Dipropionate
Therapeutic Area: Dermatology Product Name: Wynzora
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: MC2 Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
